Oncology & Cancer

Nivolumab plus ipilimumab tops sunitinib for advanced renal CA

(HealthDay)—For patients with previously untreated clear-cell advanced renal-cell carcinoma, nivolumab plus ipilimumab is associated with better overall survival than sunitinib, according to a study published online March ...

Immunology

Better cancer immunotherapy drugs through X-ray crystallography

Immunotherapy drugs to combat cancer have stimulated tremendous excitement among patients and physicians alike. They debuted in 2011, when the U.S. Food and Drug Administration approved ipilimumab (Yervoy) to treat metastatic ...

page 2 from 4